These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38406608)

  • 1. ADCOMS sensitivity versus baseline diagnosis and progression phenotypes.
    Evenden D; Prosser A; Michopoulou S; Kipps C;
    Alzheimers Dement (Amst); 2024; 16(1):e12540. PubMed ID: 38406608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the Clinical Meaningfulness of the Alzheimer's Disease Composite Score (ADCOMS) Tool.
    Tahami Monfared AA; Lenderking WR; Savva Y; Ladd MK; Zhang Q;
    Neurol Ther; 2022 Sep; 11(3):1085-1100. PubMed ID: 35513767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Staging Disease Severity Using the Alzheimer's Disease Composite Score (ADCOMS): A Retrospective Data Analysis.
    Tahami Monfared AA; Houghton K; Zhang Q; Mauskopf J;
    Neurol Ther; 2022 Mar; 11(1):413-434. PubMed ID: 35099758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials.
    Wang J; Logovinsky V; Hendrix SB; Stanworth SH; Perdomo C; Xu L; Dhadda S; Do I; Rabe M; Luthman J; Cummings J; Satlin A
    J Neurol Neurosurg Psychiatry; 2016 Sep; 87(9):993-9. PubMed ID: 27010616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's Disease Composite Score: A Post-Hoc Analysis Using Data from the LipiDiDiet Trial in Prodromal Alzheimer's Disease.
    Hendrix SB; Soininen H; van Hees AMJ; Ellison N; Visser PJ; Solomon A; Attali A; Blennow K; Kivipelto M; Hartmann T
    J Prev Alzheimers Dis; 2019; 6(4):232-236. PubMed ID: 31686094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
    Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
    Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADSS: A Composite Score to Detect Disease Progression in Alzheimer's Disease.
    Shan G; Lu X; Li Z; Caldwell JZK; Bernick C; Cummings J
    J Alzheimers Dis Rep; 2024; 8(1):307-316. PubMed ID: 38405343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease.
    Dhadda S; Kanekiyo M; Li D; Swanson CJ; Irizarry M; Berry S; Kramer LD; Berry DA
    Alzheimers Res Ther; 2022 Dec; 14(1):182. PubMed ID: 36482412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lecanemab in Early Alzheimer's Disease.
    van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
    N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's disease.
    Langbaum JB; Ellison NN; Caputo A; Thomas RG; Langlois C; Riviere ME; Graf A; Lopez Lopez C; Reiman EM; Tariot PN; Hendrix SB
    Alzheimers Res Ther; 2020 May; 12(1):66. PubMed ID: 32460855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.
    Ayutyanont N; Langbaum JB; Hendrix SB; Chen K; Fleisher AS; Friesenhahn M; Ward M; Aguirre C; Acosta-Baena N; Madrigal L; Muñoz C; Tirado V; Moreno S; Tariot PN; Lopera F; Reiman EM
    J Clin Psychiatry; 2014 Jun; 75(6):652-60. PubMed ID: 24816373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease.
    Langbaum JB; Hendrix SB; Ayutyanont N; Chen K; Fleisher AS; Shah RC; Barnes LL; Bennett DA; Tariot PN; Reiman EM
    Alzheimers Dement; 2014 Nov; 10(6):666-74. PubMed ID: 24751827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Takwoingi Y; Flicker L; Mason SE; McShane R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD008782. PubMed ID: 24913723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease: 18-Month Results from the GERAS Observational Study.
    Kahle-Wrobleski K; Andrews JS; Belger M; Ye W; Gauthier S; Rentz DM; Galasko D
    J Prev Alzheimers Dis; 2017; 4(2):72-80. PubMed ID: 29186278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.
    Chowdhury S; Chowdhury NS
    Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial.
    Abdullah L; Crawford F; Tsolaki M; Börjesson-Hanson A; Olde Rikkert M; Pasquier F; Wallin A; Kennelly S; Ait-Ghezala G; Paris D; Hendrix S; Blennow K; Lawlor B; Mullan M
    Front Neurol; 2020; 11():149. PubMed ID: 32210906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compensatory mechanisms in higher-educated subjects with Alzheimer's disease: a study of 20 years of cognitive decline.
    Amieva H; Mokri H; Le Goff M; Meillon C; Jacqmin-Gadda H; Foubert-Samier A; Orgogozo JM; Stern Y; Dartigues JF
    Brain; 2014 Apr; 137(Pt 4):1167-75. PubMed ID: 24578544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer's disease in patients with mild cognitive symptoms.
    Arvidsson I; Strandberg O; Palmqvist S; Stomrud E; Cullen N; Janelidze S; Tideman P; Heyden A; Åström K; Hansson O; Mattsson-Carlgren N
    Alzheimers Res Ther; 2024 Mar; 16(1):61. PubMed ID: 38504336
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.